Phase 2
Completed N=19
High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Source: ClinicalTrials.gov NCT02932332 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcomePrimary: Change in Dyspnea Numeric Score Between 0 and 10 Minutes — -1.8; -1.8; -0.6; -0.5 score on a scale
Summary
The goal of this clinical research study is to compare high-flow oxygen, low-flow oxygen, high-flow air, and low-flow air in helping to decrease shortness of breath in cancer patients. Researchers also want to learn if these therapies can help to improve lung function and quality of life.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Dyspnea Numeric Score Between 0 and 10 Minutes |
-1.8; -1.8; -0.6; -0.5 | — |
| SECONDARY Change in Modified Borg Scale Intensity Between 0 and 10 Minutes |
-0.7; -1.8; -0.1; -0.5 | — |
| SECONDARY Change in Modified Borg Scale Unpleasantness Between 0 and 10 Minutes |
-0.5; -1.8; -0.6; -0.7 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of cancer
- Patients seen by palliative care, thoracic oncology, pulmonary medicine, or emergency care at MD Anderson Cancer Center
- Dyspnea Numeric Rating Scale at rest >/=3 of 10 (average over last 24 hour)
- Non-hypoxemic (i.e. oxygen saturation >90% on ambient air)
- Able to communicate in English or Spanish
- Age >/= 18 years
- Able to tolerate high-flow oxygen/air
Exclusion Criteria
- Memorial Delirium Rating Scale >13
- Hemodynamic instability
- Respiratory failure requiring mechanical ventilation or non-invasive ventilation
- Frequent use of rescue opioids >8x/day or rescue bronchodilators >8x/day over last 24 hours
- Currently requiring high flow oxygen for oxygenation
Data sourced from ClinicalTrials.gov (NCT02932332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.